Another 2021 study of adults with overweight or obesity found that participants who took semaglutide lost a mean average of 14.9% of their body weight over 68 weeks. Study participants reported ...

New study reveals semaglutide outperforms liraglutide in ... Moreover, 20.3% of the study participants were Black, 7% were Hispanic, 68.5% were White, and 3.4% belonged to other races or ethnicities.

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

A recent clinical trial, led by UNC School of Medicine researchers Dr. John Buse and Dr. Matthew Cavender, found that the oral form of semaglutide significantly reduces the risk of cardiovascular ...

💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease. ️ The ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...